Trial · NCT06666322
Platform Trial For Cryptococcal Meningitis (PLATFORM-CM)
NCT06666322, Phase 2, Phase 3, Recruiting, David Boulware
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Platform Trial For Cryptococcal Meningitis (PLATFORM-CM). Trials, record NCT06666322. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06666322
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Platform Trial For Cryptococcal Meningitis (PLATFORM-CM)
- NCT number
- NCT06666322
- Status
- Recruiting
- Phases
- Phase 2, Phase 3
- Enrollment
- 2,000 participants, estimated
- Lead sponsor
- David Boulware
- Conditions
- Hiv, Cryptococcal Meningitis
- Interventions
Standard of care, Oteseconazole - antifungal therapy 1, Turletricin injection - antifungal therapy 2, Turletricin Injection - antifungal therapy 3, Oteseconazole with Flucytosine - antifungal therapy 4
- First posted
- 2024-10-30
- Last updated
- 2026-07-27
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rate of cerebrospinal fluid (CSF) Cryptococcus clearance (Early Fungicidal Activity, or EFA) | 2 weeks | quantified by the change of log 10 Cryptococcus CFU/mL CSF/day as measured by serial quantitative CSF fungal cultures over \~2 weeks. |
| Primary | All-cause mortality | 2 weeks | measured at 2-weeks |
| Secondary | Desirability of Outcome Response (DOOR) as ordinal ranked maximum score tested by Win Ratio. | 18 weeks | 1. Death by 18-weeks 2. Serious Adverse Event through 18 weeks (e.g. all-cause re- hospitalization, permanent neurologic deficit, etc.), lost to follow up before 10-weeks. 3. Grade 4 lab adverse event by 10 weeks, early discontinuation of study drug, or lost to follow up after 10 weeks. 4. Grade 3 lab adverse event by 10 weeks OR study drug interruption or dose reduction 5. Survival through 18-weeks |
| Secondary | Survival time through 18 weeks without Cryptococcus culture-positive relapse of meningitis | 18 weeks | number of participants |
| Secondary | CSF culture sterility (cumulative incidence over 18 weeks) | 18 weeks | |
| Secondary | 18-week survival time | 18 weeks | |
| Secondary | Use of rescue/additional IV amphotericin beyond scheduled use | 18 weeks | |
| Secondary | Modified Rankin score on functional status at 18 weeks | 18 weeks | |
| Secondary | Incidence of laboratory abnormalities by Grade 1-5 | 10 weeks | |
| Secondary | Incidence of serious adverse events | 18 weeks |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06666322
GET https://conductscience.org/api/trials/v1/NCT06666322/registered